TransCode Therapeutics
RNAZ
1 hedge funds and large institutions have $2.67M invested in TransCode Therapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
15% less capital invested
Capital invested by funds: $3.14M → $2.67M (-$473K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$792K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
AIGH Capital Management
Baltimore,
Maryland
| $1.62M | +$3.22M | +2 | New |
|
|
WVP
2
Worth Venture Partners
Fort Lee,
New Jersey
| $447K | – | – | – |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $252K | – | – | – |
|
|
RAM
4
Redmond Asset Management
Henrico,
Virginia
| $115K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $96K | – | – | – |
|
6
State Street
Boston,
Massachusetts
| $26K | – | – | – |
|
|
KJHP
7
K.J. Harrison & Partners
Toronto,
Ontario, Canada
| $25K | – | – | – |
|
8
Renaissance Technologies
New York
| $25K | – | – | – |
|
9
BlackRock
New York
| $20K | – | – | – |
|
|
SC
10
Shay Capital
New York
| $19K | – | – | – |
|
|
ACM
11
ACT Capital Management
Wayne,
Pennsylvania
| $8K | – | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $8K | – | – | – |
|
|
KC
13
Kepos Capital
New York
| – | -$792K | – | – |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$11K | – | – |
|
RNAZ Hedge Fund Activity: Q2 2022 in Review
1 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q2 2022, worth a combined $2.67M — down 15% from $3.14M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RNAZ positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $3.22M. The largest seller was Kepos Capital, cutting an estimated $792K.
- 1 institutional investor held TransCode Therapeutics (RNAZ) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $2.67M of TransCode Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
- 1 fund opened new TransCode Therapeutics positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest TransCode Therapeutics buyer in Q2 2022 was AIGH Capital Management, an estimated $3.22M added.
- The largest TransCode Therapeutics seller in Q2 2022 was Kepos Capital, an estimated $792K sold.
Based on aggregated 13F filings for Q2 2022.